methyl 6-(4-(3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)hexanoate | 1446713-18-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 6-(4-(3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)hexanoate
• CAS: 1446713-18-3
• 化学式: C₂₆H₂₅ClN₈O₂
• 分子量: 516.99
• InChiKey: LQVZQHMKJJZNKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.71
• 重原子数：
  37.0
• 可旋转键数：
  9.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  126.63
• 氢给体数：
  1.0
• 氢受体数：
  10.0

反应信息

• 作为反应物：
  描述：

  methyl 6-(4-(3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)hexanoate 在 盐酸羟胺 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以73%的产率得到6-[4-[3-[4-amino-3-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]phenyl]triazol-1-yl]-N-hydroxyhexanamide
  参考文献：
  名称：

  Development of a Chimeric c-Src Kinase and HDAC Inhibitor

  摘要：

  On the basis of synergism observed between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described. The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor. Chimeric inhibitor 4 is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.

  DOI：

  10.1021/ml400175d
• 作为产物：
  描述：

  3-(4-Chlorophenyl)-1-(3-ethynylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 、 6-叠氮基己酸甲酯 在 copper(l) iodide 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 以27%的产率得到methyl 6-(4-(3-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)hexanoate
  参考文献：
  名称：

  Development of a Chimeric c-Src Kinase and HDAC Inhibitor

  摘要：

  On the basis of synergism observed between a selective c-Src kinase inhibitor with an HDAC inhibitor, the development of the first chimeric c-Src kinase and HDAC inhibitor is described. The optimized chimeric inhibitor is shown to be a potent c-Src and HDAC inhibitor. Chimeric inhibitor 4 is further shown to be highly efficacious in cancer cell lines and significantly more efficacious than a dual-targeting strategy using discrete c-Src and HDAC inhibitors.

  DOI：

  10.1021/ml400175d